The greater a company's earnings, the better its position will be to pay dividends. However, Pfizer's adjusted earnings per ...

A $100,000 factor-weighted model portfolio yields about 4%, with several stocks trading near decade-high dividend yields.

Tuesday's quarterly earnings release underscored the necessity for new revenue drivers. Although Pfizer exceeded analyst expectations with earnings of $0.87 per share against projections of $0.79, ...

Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.

A judge denied Pfizer Inc.’s request to temporarily block Novo Nordisk A/S’ $10 billion bid to acquire the obesity startup ...

Metsera, Inc. (NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker Metsera.

Novo Nordisk raised its offer to $10 billion for Metsera, escalating its takeover battle with Pfizer over the drug developer.

Pfizer has won the week-long bidding war for Metsera with an upwardly revised up-to-$10 billion offer matching that of rival Novo Nordisk—and more than a little help from Washington.

Revised transaction values Metsera at up to $86.25 per share Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption ...